Meeting
2022 ASCO Annual Meeting
Micro-organospheres retain patient tumor microenvironment for precision immuno-oncology.
Authors
Shengli Ding
Xilis.Inc, Durham, NC
Shengli Ding , Naveen R. Natesh , Kassandra Spiller , Rui Xi , Daniel Nelson , Nikolche Gjorevski , Antje Walz , Estelle Marrer-Berger , Hans Clevers , Shiaowen David Hsu , Xiling Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2573)
DOI
10.1200/JCO.2022.40.16_suppl.2573
Abstract #
2573
Poster Bd #
228
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Pan-cancer B- and T-cell transcriptome analysis of CXCL13 as a predictive marker for immune checkpoint inhibitor response.
First Author: Yu Fujiwara
Poster
2023 ASCO Annual Meeting
A study of tumor neoantigen burden and HLA-LOH by whole-exome sequencing to characterize immune biomarkers of lung cancer.
First Author: Wei Wang
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Patient reported toxicities: Development and validation of patient-reported symptom measure for lung cancer patients receiving immunotherapy.
First Author: Sandra S. Shaw